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The striking, but selective, effect of nerve growth factor 
pathetic-noradrenergic branch of the autonomic nervous system in 
(NGF) on the sym- 
mammals, after 
neonatal or adult treatment, is well documented [l-3]. In studies of short-term 
effects, where the interval between treatment and measurement is of the order of 
days at most, NGF administration elevates not only the norepinephrine (NE) 
specific activity (ug/g> and tissue NE content (ug/tissue) of noradrenergically 
innervated end-organs and/or ganglia, but also the activity of enzymes specifi- 
cally involved in its (NE) synthesis. Daily treatment of newborn rats with 
10 ugfg of NGF for 10 days enhances the growth and differentiation of neuro- 
blasts in the superior cervical ganglion. Accompanying this characteristic 
morphological effect, was a selective induction (5 to 15-fold increase in speci- 
fic and total activity, respectively) of tyrosine hydroxylase (EC 1.14.3, TH) 
and dopamine-B-hydroxylase (EC 1.14.2.1, DBH), two enzymes involved in NE syn- 
thesis in noradrenergic neuronal systems. In contrast, the activities of dopa- 
decarboxylase (EC 4.1.1.26) and monamine oxidase (EC 1.4.3.4, MAO), two more 
generally distributed enzymes present as well in other cell types, increase only 
in proportion to the volume growth of the superior cervical ganglion neurons 
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[1,41. As a result of this NGF-induced functional and structural hypertrophy, 
NE content in ganglia and several peripheral tissues measured soon after NGF 
treatment is increased well over control values, in some cases by as much as 
300-400 per cent [1,3,5,6]. 
Nevertheless, there is little, if any, information on the significance of 
prior neonatal NGF treatment in the adult animal, since no study to date has 
followed up the long-term effects of early administration of NGF. Accordingly, 
some long-term effects were studied in adult mice after early NGF treatment. 
Nerve growth factor prepared from the submaxillary glands of male mice was 
administered subcutaneously (10 ug/g) to newborn male and female mice (Swiss- 
Webster) within 8 hr of birth, and continued daily for 10 consecutive days.* 
Litter-mate controls were similarly injected with an equal volume of phosphate- 
buffered (pH 7.2) physiological saline (PBS) employed as a vehicle for NGF. 
Mice were sacrificed, at approximately 9 months of age, by cervical dislo- 
cation. Spleens, hearts and brains were rapidly but carefully dissected out, 
frozen and stored in liquid nitrogen for subsequent analysis. NE content was 
analyzed as described previously for endogenous NE [8]. Briefly, Alumina 
adsorption (columns) was used to purify tissue NE for fluorimetric assay by a 
modification of the trihydroxyindole method of von Euler and Lishajko [9]. All 
values are corrected for recovery of 80 per cent, determined by carrying stan- 
dard solutions of NE through both Alumina adsorption and ferricyanide oxidation 
procedures. Tissue blanks were run for all samples in the oxidation. 
Quite unexpectedly, both cardiac and splenic NE content and specific acti- 
vity in both male and female mice after early NGF treatment were well below 
those measured in litter-mate controls [Table 11. In fact, the results 
reported here appear to be qualitatively similar, biochemically, to results 
obtained after treatment of neonates with NGF-antiserum, where decreases in NE 
content of peripheral tissues are expected, and have been reported by many 
investigators 121. The absence of this time-dependent reversal of NGF-induced 
short-term increases in tissue NE in brain can be attributed to the inability of 
the large NGF protein molecule to cross the blood-brain barrier. 
To our knowledge, a change in adult mouse peripheral tissue NE content 
of the magnitude and direction found here after neonatal NGF treatment has not 
WGF was purified according to a modification of the procedure of Cohen[7]. 
Neonatal treatment included a few animals injected instead with a commercial 
NGF preparation (Wellcome Reagents MR60, 3 ug/g/day) for 6 consecutive days. 
Since the same results were obtained with these animals, they are included in 
this report. 
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Table 1. Norepinephrine Content of Adult Male and Female Mouse Spleen, Heart 
and Brain after Neonatal NGF Treatment 
Values are expressed on both a total content (ngftissue) and specific 
activity (ng/g> basis. (a) % DEC: NE/tissue after PBS - NE/tissue after NGF 
NE/tissue after PBS 
(bf wet weight: expressed in mg; one value for female heart is omitted be- 
cause of a blotting error. (c> S : significance of difference (L-test), 
experimental (NGF) treatment vs c&trol (PBS), treatment. (d) S2: signffi- 
cance of difference (L-test), males vs females. 
previously been reported. Nevertheless, two recent publications, concerning a 
time-dependent reversibility of the NGF effect, may be related to our present 
finding. Edwards et al. I101 have reported that, after an initial NGF-induced -- 
increase in mouse superior cervical ganglion weight (cell number and cell size) 
observed within 1. day after a bday neonatal injection schedule (5 &g/day), 
values appear to return by 44 days to those seen in 44-day-old control animals. 
Similarly, Hendry [llJ has shown that the increased production of tyrosine 
hydroxylase observed %mmediately after neonatal NGF administration (3 uglglday 
for 6-10 days) returns to control values 1-2 months later. In addition, pre- 
liminary results indicate that, by 5 months of age, NE content and 3H-NE uptake 
of peripheral tissues did not differ between early NGF (1 up/g)- and saline- 
injected mice [R. J. Campbell, E. A. Stone and L. V. DiCara, unpublished 
observation]. 
Although no definitive explanation of these results is yet possible, two 
plausible directions might be uentioned. Abnormally high levels of exogenous 
NGF, widely distributed rather than more specifically located endogenously in 
various end-organs during the neonatal period, would result from daily NGF 
injections. It is possible that this elevated NGF shuts off, via a feedback 
mechanism, or antagonizes, via production of inactivating antibodies, (develop- 
ment of) the physiological NGF-producing mechanisms subserving development and 
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maintenance of peripheral noradrenergic neuronal systems. A second possibility 
depends upon the NGF-altered balance between the NE-synthesizing enzymes (TH and 
DSH) and the intracellular NE-deaminating enzyme (MAO): noradrenergic nerve 
terminal destruction may occur when NE metabolism is altered such that the 
ratio lH x DBH 
MAO 
is increased, with the resultant excess dopamine and/or dopamine- 
8-hydroxylase leading to dopamine-ortho-quinone formation in the terminals. In 
this regard, it is interesting to note that growth and extension of neurites in 
sympathetic neuroblasts in vitro are adversely affected by higher than optimal 
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